We serve Chemical Name:4-Bromo-2-methylbenzo[d]thiazole CAS:112146-10-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![4-Bromo-2-methylbenzo[d]thiazole](https://a.dearchem.com/CAS2/112146-10-8.png)
Chemical Name:4-Bromo-2-methylbenzo[d]thiazole
CAS.NO:112146-10-8
Synonyms:4-bromo-2-methyl-1,3-benzothiazole
Molecular Formula:C8H6BrNS
Molecular Weight:228.10900
HS Code:2934200090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:41.13000
Exact Mass:226.94000
LogP:3.36720
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-bromo-2-methyl-1,3-benzothiazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-bromo-2-methyl-1,3-benzothiazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-bromo-2-methyl-1,3-benzothiazole Use and application,4-bromo-2-methyl-1,3-benzothiazole technical grade,usp/ep/jp grade.
Related News: The American Heart Association explains that metabolic syndrome — a grouping of five different conditions — elevates the risk for such illnesses. Abdominal obesity is one such condition; the other four include high blood sugar, high triglycerides, high blood pressure and low levels of good” HDL cholesterol.
Bariatric surgery — including sleeve gastrectomy and gastric bypass — offers an opportunity to reduce such risk by helping patients achieve considerable weight loss, the investigators said.
In fact, the study team noted that bariatric surgery is the standard of care for severely obese patients. Severe obesity is defined as having a body mass index (BMI) of 40, or a BMI of 35 and up alongside obesity-related complications such as diabetes.
Using insurance claims data, Schimpke and his team focused on a pool of nearly 1.8 million patients across the United States who were severely obese — and therefore eligible for bariatric surgery — in the decade beginning 2010.
Of those, roughly 100,000 actually underwent bariatric surgery during that time frame. But procedure patterns varied widely by state.
For example, while between roughly 9% and 10.4% of eligible patients in New Jersey, Rhode Island and Delaware opted for surgery, less than 3% did so in West Virginia, Alabama and Arkansas.
Overall, the researchers determined that the lowest in opt-in rates by region was the Midwest, where just over 4% of eligible patients underwent surgery, despite the fact that nearly 34% of Midwesterners are obese (making the region home to the highest overall obesity rates in the country).
By contrast, the highest opt-in surgery rate (nearly 8%) was seen in the Northeast region, where the overall obesity rate is lower (29%).
The findings were presented last week at a virtual meeting of the American Society for Metabolic and Bariatric Surgery. Such research is considered preliminary until published in a peer-reviewed journal.
“There are likely several contributing factors to the wide variation in utilization,” said Schimpke. He highlighted differences in: levels of access to medical care; beliefs and attitudes among patients and referring physicians; number of available hospitals and surgeons; and insurance coverage requirements.
Schimpke also pointed to the “negative psycho-social connotation associated with bariatric surgery among both physicians/practitioners and patients, which needs to be addressed with strategic campaigns detailing the safety and efficacy of bariatric surgery. 4-Bromo-2-methylbenzo[d]thiazole manufacturer Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells. 4-Bromo-2-methylbenzo[d]thiazole supplier In the context of the new medicine policy, with the development of China’s R & D strength, the number of innovative drugs approved has been blown out, which further strengthened the demand and speed of industrialization of raw materials in China. 4-Bromo-2-methylbenzo[d]thiazole vendor In the context of the new medicine policy, with the development of China’s R & D strength, the number of innovative drugs approved has been blown out, which further strengthened the demand and speed of industrialization of raw materials in China. 4-Bromo-2-methylbenzo[d]thiazole factory Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview.
Bariatric surgery — including sleeve gastrectomy and gastric bypass — offers an opportunity to reduce such risk by helping patients achieve considerable weight loss, the investigators said.
In fact, the study team noted that bariatric surgery is the standard of care for severely obese patients. Severe obesity is defined as having a body mass index (BMI) of 40, or a BMI of 35 and up alongside obesity-related complications such as diabetes.
Using insurance claims data, Schimpke and his team focused on a pool of nearly 1.8 million patients across the United States who were severely obese — and therefore eligible for bariatric surgery — in the decade beginning 2010.
Of those, roughly 100,000 actually underwent bariatric surgery during that time frame. But procedure patterns varied widely by state.
For example, while between roughly 9% and 10.4% of eligible patients in New Jersey, Rhode Island and Delaware opted for surgery, less than 3% did so in West Virginia, Alabama and Arkansas.
Overall, the researchers determined that the lowest in opt-in rates by region was the Midwest, where just over 4% of eligible patients underwent surgery, despite the fact that nearly 34% of Midwesterners are obese (making the region home to the highest overall obesity rates in the country).
By contrast, the highest opt-in surgery rate (nearly 8%) was seen in the Northeast region, where the overall obesity rate is lower (29%).
The findings were presented last week at a virtual meeting of the American Society for Metabolic and Bariatric Surgery. Such research is considered preliminary until published in a peer-reviewed journal.
“There are likely several contributing factors to the wide variation in utilization,” said Schimpke. He highlighted differences in: levels of access to medical care; beliefs and attitudes among patients and referring physicians; number of available hospitals and surgeons; and insurance coverage requirements.
Schimpke also pointed to the “negative psycho-social connotation associated with bariatric surgery among both physicians/practitioners and patients, which needs to be addressed with strategic campaigns detailing the safety and efficacy of bariatric surgery. 4-Bromo-2-methylbenzo[d]thiazole manufacturer Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells. 4-Bromo-2-methylbenzo[d]thiazole supplier In the context of the new medicine policy, with the development of China’s R & D strength, the number of innovative drugs approved has been blown out, which further strengthened the demand and speed of industrialization of raw materials in China. 4-Bromo-2-methylbenzo[d]thiazole vendor In the context of the new medicine policy, with the development of China’s R & D strength, the number of innovative drugs approved has been blown out, which further strengthened the demand and speed of industrialization of raw materials in China. 4-Bromo-2-methylbenzo[d]thiazole factory Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview.
